V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10007361 | 10005218 | 1.68 | 70 | Adjuvant (A) | 2015-03-23 | 2015-05-08 | EOX | 2 | N | 10539022 | NIVOLUMAB |
| 10007362 | 10005219 | 1.65 | 69 | Disease modification (D) | 2014-12-02 | 2014-12-07 | FLUOROURACIL + MITOMYCIN + RT | 02 | N | 10539033 | CVP R + GEMCITABINE |
| 10007363 | 10005220 | 1.8 | 89 | Curative (C) | 2018-05-04 | 2018-05-10 | Bortezomib + Panobinostat | N | null | 10539671 | CHLVPP |
| 10007364 | 10005222 | 1.8 | 90 | Curative (C) | 2017-10-31 | 2018-03-07 | CAV | 02 | N | 10539770 | CISPLATIN + FLUOROURACIL |
| 10007365 | 10005223 | 1.82 | 95 | null | 2015-04-06 | 2015-08-17 | Cisplatin + Pemetrexed | N | N | 10539942 | CLADRIBINE |
| 10007366 | 10005223 | null | 91.2 | Curative (C) | 2017-06-04 | 2017-06-04 | VEPEMB | 1 | N | 10539942 | DA |
| 10007367 | 10005224 | 1.83 | 84.8 | Radical (R) | 2016-10-09 | 2016-10-11 | MaxiCHOP (>Cycle 2) | N | N | 10540589 | MELPHALAN |
| 10007368 | 10005225 | 1.75 | null | Curative (C) | 2017-11-17 | 2017-11-18 | Cabazitaxel | N | N | 10540927 | DOCETAXEL + NINTEDANIB |
| 10007369 | 10005226 | 1.7 | 91 | Disease modification (D) | 2018-04-16 | 2018-06-25 | CYCLOPHOSPHAMIDE + ETOPOSIDE + Procarbazine | N | N | 10540976 | IRINOTECAN |
| 10007370 | 10005227 | 1.8 | 102 | Curative (C) | 2015-11-24 | 2015-12-11 | DHAP - R | N | null | 10541003 | CAPECITABINE + MITOMYCIN |
| 10007371 | 10005230 | 1.65 | null | Palliative (P) | 2018-08-03 | 2018-09-01 | Capecitabine + Mitomycin | N | N | 10541130 | CARBOPLATIN + PACLITAXEL + RT |
| 10007372 | 10007606 | null | 59.75 | null | null | 2018-08-13 | Bevacizumab + CAPECITABINE + OXALIPLATIN | N | N | 10541154 | HYDROXYCARBAMIDE |
| 10007373 | 10007606 | 1.74 | 80 | Neo-adjuvant (N) | 2016-02-06 | 2016-02-07 | EOX | null | N | 10541154 | ENZALUTAMIDE |
| 10007374 | 10007606 | 1.71 | 70 | Palliative (P) | null | 2019-04-04 | MYELOMA XI TRIAL | N | N | 10541154 | CETUXIMAB |
| 10007375 | 10005235 | null | 79 | Disease modification (D) | 2016-01-22 | 2016-09-03 | GDP | N | Y | 10541495 | INCA TRIAL |
| 10007376 | 10007607 | null | 61.8 | Palliative (P) | 2017-06-13 | 2018-02-24 | Cyclophosphamide High Dose | null | N | 10541515 | VISMODEGIB |
| 10007377 | 10005236 | 1.61 | 110.3 | Curative (C) | 2016-11-02 | 2016-11-23 | BEAM | N | N | 10541907 | EOX |
| 10007378 | 10005238 | 1.79 | null | Palliative (P) | 2018-03-14 | 2018-03-29 | OXALIPLATIN + MDG + PANITUMUMAB | 02 | N | 10542182 | OXALIPLATIN + MDG + PANITUMUMAB |
| 10007379 | 10005240 | 1.63 | 58 | Palliative (P) | 2018-11-09 | 2018-11-15 | Erlotinib | 02 | N | 10542223 | AML18 TRIAL |
| 10007380 | 10005241 | 1.72 | 72.6 | null | 2016-11-27 | 2018-10-19 | Docetaxel + Nintedanib | N | N | 10542282 | AFLIBERCEPT + FU + IRINOTECAN |
| 10007381 | 10007610 | 1.7 | 88 | Curative (C) | 2018-08-29 | 2018-08-30 | CISPLATIN + VINORELBINE + RT | 02 | N | 10542282 | CAV |
| 10007382 | 10005242 | null | 66 | Palliative (P) | 2018-12-07 | 2018-12-26 | Vinorelbine (oral) | 2 | N | 10542351 | PANITUMUMAB |
| 10007383 | 10005243 | 1.82 | 74.5 | Not known (9) | 2018-12-04 | 2019-01-09 | CETUXIMAB + IRINOTECAN + MDG | 02 | Y | 10542373 | MITOMYCIN |
| 10007384 | 10005244 | 1.74 | 63.7 | Disease modification (D) | null | 2017-12-12 | ECX | N | N | 10542654 | MELPHALAN |
| 10007385 | 10005245 | 1.76 | 91 | Adjuvant (A) | null | 2018-12-29 | EOX | N | null | 10542683 | CETUXIMAB |
| 10007386 | 10005247 | 1.71 | 73 | Palliative (P) | 2017-06-04 | 2017-06-04 | Docetaxel + Gemcitabine with GCSF | N | N | 10542737 | CAPECITABINE + GEMCITABINE |
| 10007387 | 10005248 | null | null | Adjuvant (A) | 2018-01-05 | 2018-01-29 | TAC | 02 | N | 10543189 | BENDAMUSTINE + OBINUTUZUMAB |
| 10007388 | 10005248 | 1.6 | 53.7 | Disease modification (D) | 2015-11-24 | 2015-11-26 | PERTUZUMAB + TRASTUZUMAB | 2 | N | 10543189 | DOCETAXEL + TRASTUZUMAB |
| 10007389 | 10005249 | null | 63.2 | Curative (C) | 2016-12-08 | 2016-12-21 | CHLORAMBUCIL + OBINUTUZUMAB | N | null | 10543551 | CISPLATIN + VINORELBINE + RT |
| 10007390 | 10005249 | 1.63 | 79.5 | Palliative (P) | 2017-12-16 | 2017-12-16 | VEPEMB | 02 | N | 10543551 | FLUOROURACIL + IRINOTECAN + OXALIPLATIN |
| 10007391 | 10005250 | 1.64 | 65.9 | Adjuvant (A) | 2017-08-01 | 2017-08-07 | Pertuzumab (Maintenance) | N | N | 10543662 | TOPOTECAN |
| 10007392 | 10005252 | null | 79.3 | Not known (9) | 2019-05-18 | 2019-05-19 | Nilotinib | 02 | N | 10543801 | METHOTREXATE INTRATHECAL |
| 10007393 | 10005254 | 1.69 | 70 | Palliative (P) | 2017-12-31 | 2018-01-03 | ECX | 02 | Y | 10543913 | BUSULPHAN |
| 10007394 | 10005254 | 1.84 | 91 | Palliative (P) | 2017-11-16 | 2017-11-23 | EOX | 2 | N | 10543913 | CISPLATIN + GEMCITABINE |
| 10007395 | 10005256 | 1.66 | 60.1 | Curative (C) | 2017-08-31 | 2017-09-21 | CYCLOPHOSPHAMIDE + GEMCITABINE + RITUXIMAB + VINCRISTINE | 2 | N | 10544006 | CISPLATIN + RT |
| 10007396 | 10007619 | null | 69 | Palliative (P) | 2016-11-22 | 2017-03-18 | Trifluridine + Tipiracil | N | N | 10544017 | METHOTREXATE HIGH DOSE |
| 10007397 | 10005258 | null | 75.9 | Palliative (P) | 2014-02-24 | 2014-02-25 | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | N | N | 10544017 | BORTEZOMIB |
| 10007398 | 10005259 | 1.63 | 57 | Adjuvant (A) | 2014-08-17 | 2014-08-20 | CISPLATIN + VINORELBINE + RT | N | N | 10544223 | CETUXIMAB + IRINOTECAN + MDG |
| 10007399 | 10005261 | 1.59 | null | Adjuvant (A) | 2015-11-13 | 2015-12-04 | Panitumumab | N | null | 10544323 | IRINOTECAN |
| 10007400 | 10005263 | 1.75 | 69.6 | Disease modification (D) | 2015-06-20 | 2015-06-20 | Cisplatin + Etoposide po | N | null | 10544405 | VINORELBINE |
| 10007401 | 10005263 | 1.77 | null | Adjuvant (A) | 2018-06-03 | 2018-07-10 | Cetuximab 14 day | N | N | 10544405 | GEMTUZUMAB OZOGAMICIN |
| 10007402 | 10005263 | 1.77 | 52.7 | Curative (C) | 2018-02-06 | 2018-12-20 | Enzalutamide | null | null | 10544405 | GEMCARBO + RITUXIMAB |
| 10007403 | 10005266 | 1.69 | 65.1 | Disease modification (D) | 2016-02-29 | 2016-02-29 | Cisplatin+Gemcitabine (gallbladder) | N | N | 10544598 | CHLORAMBUCIL |
| 10007404 | 10005270 | 1.79 | 98.3 | Adjuvant (A) | 2015-02-26 | 2015-03-22 | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB | N | N | 10544806 | CETUXIMAB |
| 10007405 | 10005271 | 1.77 | 61.6 | Palliative (P) | 2017-10-30 | 2017-12-03 | CHLORAMBUCIL + RITUXIMAB | 2 | N | 10544882 | BORTEZOMIB + THALIDOMIDE |
| 10007406 | 10005272 | 1.53 | 71 | Adjuvant (A) | 2017-02-17 | 2017-03-17 | CISPLATIN + GEMCITABINE | 02 | N | 10545005 | CAPECITABINE + MITOMYCIN |
| 10007407 | 10005273 | 1.57 | 57 | Palliative (P) | 2018-04-18 | 2018-04-19 | Liposomal Doxorubicin 40mg/m2 | N | N | 10545093 | CYCLOPHOSPHAMIDE |
| 10007408 | 10005275 | 1.75 | 100 | Palliative (P) | 2015-12-28 | 2015-12-29 | Cyclophosphamide oral | N | null | 10545106 | NINTEDANIB |
| 10007409 | 10007626 | 1.64 | 71.4 | Palliative (P) | 2015-09-14 | 2017-09-30 | Gemcitabine + Capecitabine | N | Y | 10545551 | IRINOTECAN |
| 10007410 | 10005277 | 1.74 | 79 | Palliative (P) | 2016-12-11 | 2016-12-12 | EOX | N | N | 10545578 | VENETOCLAX |